Infant ALL occurs in children ages 1 year and younger. ALL in infants is rare. About 90 cases occur each year in the United States. Infant ALL is different from ALL in older children. Treating cancer in infants is a challenge. Infant ALL is usually aggressive. The main treatment is …

On average, MLL-r infant ALL (which is the most thoroughly studied subtype of MLL-r leukemias) expresses 37-fold higher FLT-3 protein compared to normal bone marrow and 2- and 16-fold higher expression of FLT-3 compared to non-MLL-r ALL in children less than 1 year of age and older children, respectively (150, 152).

Dec 9, 2022 · Outcomes for infants diagnosed under 1 year of age with KMT2A -rearranged acute lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years.

Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical presentation in a uniquely vulnerable host, its poor response to current therapies, and its unique biology that is increasingly pointing the way toward novel therapeutic approaches.

Jul 8, 2019 · Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers.

Jan 17, 2019 · Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.

Natural history and molecular studies indicate that infant acute lymphoblastic leukaemia (ALL) originates in utero, is distinct from childhood ALL, and most cases are caused by MLL-r resulting in an oncogenic MLL fusion protein.

Infant leukemias have a high frequency of mixed lineage leukemia (MLL) gene rearrangements. Using data from a large etiologic study, we evaluated the distribution of selected demographic factors among 374 infant leukemia cases by leukemic subtype, ...

Oct 15, 2020 · In the Japanese Pediatric Leukemia/Lymphoma Study Group MLL-10 trial, infants with ALL were stratified into 3 risk groups (low risk [LR], intermediate risk [IR], and high risk [HR]) according to KMT2A status, age, and presence of central nervous system leukemia.

Acute lymphoblastic leukemia (ALL) in infants less than 1 year of age is rare and the biological features are different from ALL in older children. 1 Infant ALL is characterized by a high frequency of rearrangements of the MLL gene (MLL-R) and heterogeneous outcome.